Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhangReuters • 03/04/26
Moderna's stock rallies more than 10% as deal over a patent dispute clears vaccine pipelineMarket Watch • 03/03/26
Moderna, Inc. (MRNA) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/03/26
Roivant Announces Genevant Sciences' and Arbutus Biopharma's $2.25 Billion Global Settlement With ModernaGlobeNewsWire • 03/03/26
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With ModernaGlobeNewsWire • 03/03/26
MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo ShotZacks Investment Research • 03/02/26
European Medicines Agency's Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna's mRNA Combination Vaccine Against Influenza and COVID-19Accesswire • 02/27/26
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the costReuters • 02/23/26
Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is ClearThe Motley Fool • 02/23/26
Billionaire Philippe Laffont Just Dumped CoreWeave and Opened a Position in a Stock That Soared Nearly 50% in January.The Motley Fool • 02/21/26